The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis
Open accessAbstract
BACKGROUND AND OBJECTIVES: Addition of aldosterone antagonists (AA) might provide renal benefits to proteinuric chronic kidney disease (CKD) patients over and above the inhibition of renin-angiotensin system blockers (RAS). We evaluated the benefits and harms of adding selective and nonselective AA in CKD patients already on RAS. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: MEDLINE, EMBASE, and Renal Health Library were searched for relevant randomized clinical trials in adult CKD patients. Results were summarized using the random-effects model. RESULTS: Eleven trials (991 patients) were included. In comparison to angiotensin- converting enzyme inhibitors (ACEi) and/or angiotensin receptor blockers (ARB) plus placebo, nonselective AA along with ACEi and/or ARB significantly reduced 24 h proteinuria (seven trials, 372 patients, weighted mean difference [WMD] -0.80 g, 95% CI -1.27, -0.33) and BP. This did not translate into an improvement in GFR (WMD -0.70 ml/min/1.73m(2), 95% CI -4.73, 3.34). There was a significant increase in the risk of hyperkalemia with the addition of nonselective AA to ACEi and/or ARB (relative risk 3.06, 95% CI 1.26, 7.41). In two trials, addition of selective AA to ACEi resulted in an additional reduction in 24 h proteinuria, without any impact on BP and renal function. Data on cardiovascular outcomes, long-term renal outcomes and mortality were not available in any of the trials. CONCLUSIONS: Aldosterone antagonists reduce proteinuria in CKD patients already on ACEis and ARBs but increase the risk of hyperkalemia. Long-term effects of these agents on renal outcomes, mortality, and safety need to be established.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rachmani, R., Slavachevsky, I., Amit, M., Levi, Z., Kedar, Y., Berla, M., & Ravid, M. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01194.x · Cited by 142
RetractedMeasuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
Juurlink, D. N., Mamdani, M. M., Lee, D. S., Kopp, A., Austin, P. C., Laupacis, A., & Redelmeier, D. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040135 · Cited by 1,761
Jafar, T. H., Schmid, C. H., Landa, M., Giatras, I., Toto, R., Remuzzi, G., Maschio, G., Brenner, B. M., Kamper, A., Zucchelli, P., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-2-200107170-00007 · Cited by 1,092
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Pitt, B., Wj, R., Zannad, F. M., Neaton, J. D., Martínez, F. A., Roniker, B., Bittman, R. M., Hurley, S., Kleiman, J. H., & Gatlin, M. R. (2003) · Cited by 708
Grassmann, A., Gioberge, S., Moeller, S., & Brown, G. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi159 · Cited by 566
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 496
Role of aldosterone in the remnant kidney model in the rat.
Greene, E. L., Kren, S., & Hostetter, T. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118867 · Cited by 479
Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes
Epstein, M., Williams, G. H., Weinberger, M., Lewin, A., Krause, S., Mukherjee, R., Patni, R., & Beckerman, B. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00240106 · Cited by 459
Myocardial Production of Aldosterone and Corticosterone in the Rat
Silvestre, J.-S., Robert, V., Heymes, C., Aupetit-Faisant, B., Mouas, C., Moalic, J.-M., Swynghedauw, B., & Delcayre, C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.4883 · Cited by 446
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339
Bianchi, S., Bigazzi, R., & Campese, V. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001854 · Cited by 338
Rossing, K., Schjoedt, K. J., Smidt, U. M., Boomsma, F., & Parving, H.-H. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2106 · Cited by 299
Strippoli, G. F., Bonifati, C., Craig, M. E., Navaneethan, S. D., & Craig, J. C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006257 · Cited by 265
Self-citationBomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261
Beneficial impact of spironolactone in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P., Tarnow, L., & Parving, H.-H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00756.x · Cited by 239
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Tarnow, L., Rossing, P., & Parving, H. H. (2006) · Kidney International · doi:10.1038/sj.ki.5001580 · Cited by 215
Chrysostomou, A., Pedagogos, E., MacGregor, L., & Becker, G. J. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01040905 · Cited by 211
Mathiesen, E. R., Hommel, E., Hansen, H. P., Smidt, U. M., & Parving, H.-H. (1999) · BMJ · doi:10.1136/bmj.319.7201.24 · Cited by 192
van den Meiracker, A. H., Baggen, R. G., Pauli, S., Lindemans, A., Vulto, A. G., Poldermans, D., & Boomsma, F. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000249708.44016.5c · Cited by 187
Phillips, C. O., Kashani, A., Ko, D. K., Francis, G., & Krumholz, H. M. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.18.1930 · Cited by 184
Regression of Existing Glomerulosclerosis by Inhibition of Aldosterone
Aldigier, J. C., Kanjanbuch, T., Ma, L.-J., Brown, N. J., & Fogo, A. B. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090804 · Cited by 171
Aldosterone antagonists for preventing the progression of chronic kidney disease
Navaneethan, S. D., Nigwekar, S. U., & Strippoli, G. F. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007004 · Cited by 166
Self-citationBowman, J. D., Kim, H., & Bustamante, J. J. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1138 · Cited by 137
Aldosterone in Chronic Kidney and Cardiac Disease
Hostetter, T. H., & Ibrahim, H. N. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000086472.65806.73 · Cited by 137
Epstein, M. (2002) · American Journal of Hypertension · doi:10.1016/s0895-7061(02)02333-6 · Cited by 116
Tylicki, L., Rutkowski, P., Renke, M., Larczyński, W., Aleksandrowicz, E., Łysiak−Szydłowska, W., & Rutkowski, B. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.02.297 · Cited by 104
Furumatsu, Y., Nagasawa, Y., Tomida, K., Mikami, S., Kaneko, T., Okada, N., Tsubakihara, Y., Imai, E., & Shoji, T. (2008) · Hypertension Research · doi:10.1291/hypres.31.59 · Cited by 97
Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade
Griffin, K. A., & BIDANI, A. K. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02231205 · Cited by 97
Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy
Strippoli, G. F., Craig, M. E., Schena, F. P., & Craig, J. C. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004080634 · Cited by 78
Self-citationRetarding the progression of renal disease
Brenner, B. M. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.t01-2-00052.x · Cited by 74
The future of renoprotection: Frustration and promises
Schieppati, A., & Remuzzi, G. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00340.x · Cited by 54
Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome
Nakhoul, F. M., Khankin, E. V., Yaccob, A., Kawachi, H., Karram, T., Awaad, H., Nakhoul, N., Hoffman, A., & Abassi, Z. A. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00524.2007 · Cited by 25
The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy
Sica, D. (2007) · Current Drug Safety · doi:10.2174/157488607779315499 · Cited by 17
Tylicki, L., Rutkowski, P., Renke, M., & Rutkowski, P. L. (2007) · Kidney International · doi:10.1038/sj.ki.5002511 · Cited by 17
Cited by
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Agarwal, R., Kolkhof, P., Bakris, G., Bauersachs, J., Haller, H., Wada, T., & Zannad, F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa736 · Cited by 638
VI Diretrizes Brasileiras de Hipertensão
(2010) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2010001700001 · Cited by 596
Kosiborod, M., Rasmussen, H. S., Lavin, P., Qunibi, W. Y., Spinowitz, B., Packham, D., Roger, S. D., Yang, A., Lerma, E., & Singh, B. (2014) · JAMA · doi:10.1001/jama.2014.15688 · Cited by 415
Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status
Ma, T. K., Kam, K. K., Yan, B. P., & Lam, Y. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00750.x · Cited by 364
Metadata
- Authors
- Navaneethan, S. D., Nigwekar, S. U., Sehgal, A. R., & Strippoli, G. F. M.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2009-03
- Volume
- 4
- Issue
- 3
- Pages
- 542-551
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2123656765
- Cited by
- 258
- References
- 46
- FWCI
- 18.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.